Pasar al contenido principal

ESTRES DEL RETICULO ENDOPLASMICO Y SEÑALIZACION DE JNK EN LA INFLAMACION CRONICA: COMPRENDIENDO EL CAMINO A LA MALIGNIFICACION EPITELIAL

PID2020-117941RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

  • Guo, Feifei
  • Estévez-Vázquez, Olga
  • Benedé-Ubieto, Raquel
  • Maya-Miles, Douglas
  • Zheng, Kang
  • Gallego-Durán, Rocío
  • Rojas, Ángela
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Philip, Kaye
  • Egbuniwe, Isioma U.
  • Chen, Chaobo
  • Simon, Jorge
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
  • Sun, Jie
  • Reissing, Johanna
  • Bruns, Tony
  • Lamas-Paz, Arantza
  • Gómez del Moral, Manuel
  • Woitok, Marius Maximilian
  • Vaquero, Javier
  • Regueiro, José R.
  • Liedtke, Christian
  • Trautwein, Christian
  • Bañares, Rafael
  • Cubero, Javier
  • Nevzorova, Yulia A.
Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC. We analyzed the impact of the proto-oncogene c-MYC in the development of human and murine MAFLD and MAFLD-associated HCC., This work was supported by the MINECO Retos SAF2016-78711, SAF2017-87919-R, PID2020-117827RB-IOO, PID2020-117941RB-IOO, PID2020-117116RB-I00, EXOHEP-CM S2017/BMD-3727, NanoLiver-CM Y2018/NMT-4949, AMMF 2018/117, COST Action CA17112 and UCM-25/2019, La Caixa Foundation Program HR17-00601; Asociación Española Contra el Cáncer (AECC PROYE20084REGU); the German Research Foundation (SFB1382 Project ID 403224013/A02). FJC and YAN are Ramón y Cajal Researchers RYC-2014-15242 and RYC-2015-17438, respectively. FJC is a Gilead Liver Research Scholar. The research group belongs to the validated Research Groups Ref. 970935 “Liver Pathophysiology”, 920631 “Lymphocyte immunobiology”, 920361 “Inmunogenética e inmunología de las mucosas” and IBL-6 (imas12-associated). FG and KZ are Chinese Scholarship Council (CSC) fellows. O.E.-V is supported by Beca FPI associated to MINECO SAR2017-87919R and R.B.-U by programa de Financiación de Universidad Complutense de Madrid—Banco Santander, CT63/19. DMM contract is supported by CIBEREHD. DMM, MRG, AR, JA and RG receive support from the Andalusian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018) and from the Instituto de Salud Carlos III (PI16/01842, PI19/01404; PI19/00589). TB is supported by the German Research Foundation (SFB1382 Project ID 403224013/B07)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea-Usandizaga, Naroa
  • Bravo, Miren
  • Egia-Mendikute, Leire
  • Abecia, Leticia
  • Serrano-Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos-García, Marc
  • Rodríguez-Agudo, Rubén
  • Araujo-Legido, Raquel
  • López-Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Peña-Cearra, Ainize
  • Simón, Jorge
  • Benedé-Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar-Bermeo, Julio
  • Martí, Nuria
  • Varela-Rey, Marta
  • Falcón-Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero, Francisco J.
  • Saura, Domingo
  • Martínez-Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Palazón, Asís
  • Sancho-Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J. G.
  • Martín, Franz
  • Martínez-Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD., This work was supported by grants from Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for Jorge Simon and Maria Luz Martinez-Chantar); Ministerio de Economía, Industria y Competitividad, Retos a la Sociedad AGL2017- 86927R (for F.M.); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 and DTS21/00094 (for Jorge Simon and Maria Luz Martinez-Chantar, and Asis Palazon. respectively); Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias co-founded by European Regional Development Fund/European Social Fund, “Investing in your future” PI19/00819, “Una manera de hacer Europa” FIS PI20/00765, and PI21/01067 (for Jose J. G. Marin., Pau Sancho-Bru,. and Mario F. Fraga respectively); Departamento de Industria del Gobierno Vasco (for Maria Luz Martinez-Chantar); Asturias Government (PCTI) co-funding 2018-2023/ FEDER IDI/2021/000077 (for Mario F. Fraga.); Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00, CEX2021-001136-S PID2020-117941RB-I00, PID2020-11827RB-I00 and PID2019-107956RA-100 integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER (for Maria Luz Martinez- Chantar, Francisco J Cubero., Yulia A Nevzorova and Asis Palazon); Ayudas Ramón y Cajal de la Agencia Estatal de Investigación RY2013-13666 and RYC2018- 024183-I (for Leticia Abecia and Asis Palazon); European Research Council Starting Grant 804236 NEXTGEN- IO (for Asis Palazon); The German Research Foundation SFB/TRR57/P04, SFB1382-403224013/ A02 and DFG NE 2128/2-1 (for Francisco J Cubero and Yulia A Nevzorova); National Institute of Health (NIH)/National Institute of Alcohol Abuse and Alcoholism (NIAAA) 1U01AA026972-01 (For Pau Sancho-Bru); Junta de Castilla y León SA074P20 (for Jose J. G. Marin); Junta de Andalucía, Grupo PAIDI BIO311 (for Franz Martin); CIBERER Acciones Cooperativas y Complementarias Intramurales ACCI20-35 (for Mario F. Fraga); Ministerio de Educación, Cultura y Deporte FPU17/04992 (for Silvia Ariño); Fundació Marato TV3 201916-31 (for Jose J. G. Marin.); Ainize Pena-Cearra is a fellow of the University of the Basque Country (UPV/ EHU); BIOEF (Basque Foundation for Innovation and Health Research); Asociación Española contra el Cáncer (Maria Luz Martinez-Chantar and Teresa C. Delgado.); Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for Maria Luz Martinez-Chantar); La Caixa Foundation Program (for Maria Luz Martinez-Chantar); Proyecto Desarrollo Tecnologico CIBERehd (for Maria Luz Martinez-Chantar); Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

  • Gutiérrez, Alejandro H.
  • Mazariegos, Marina
  • Alemany, Susana
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Sanz-García, Carlos
The cytoplasmic protein tumor progression locus 2 (TPL2), also known as cancer Osaka thyroid (Cot), or MAP3K8, is thought to have a significant role in a variety of cancers and illnesses and it is a key component in the activation pathway for the expression of inflammatory mediators. Despite the tight connection between inflammation and TPL2, its function has not been extensively studied in chronic liver disease (CLD), a major cause of morbidity and mortality worldwide. Here, we analyze more in detail the significance of TPL2 in CLD to shed light on the pathological and molecular transduction pattern of TPL2 during the progression of CLD. This might result in important advancements and enable progress in the diagnosis and treatment of CLD., This work has received funding from the MICINN Retos PID2020-113299RA-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, PID2020-116146RB-I00 all of which were cofinanced with Fondos FEDER. The European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and COST Action CA17112. CSG is an Atracción de Talento (CAM) Researcher 2019-T1/BMD-13313., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress

  • Martín-Adrados, Beatriz
  • Wculek, Stefanie K.
  • Fernández-Bravo, Sergio
  • Torres-Ruiz, Raúl
  • Valle-Noguera, Ana
  • Gómez-Sánchez, María José
  • Hernández-Walias, José Carlos
  • Moraes Ferreira, Frederico
  • Corraliza, Ana María
  • Sancho, David
  • Esteban, Vanesa
  • Rodríguez-Perales, Sandra
  • Cruz-Adalia, Aránzazu
  • Nakaya, Helder I.
  • Salas, Azucena
  • Bernardo, David
  • Campos-Martín, Yolanda
  • Martínez-Zamorano, Elena
  • Muñoz-López, Diego
  • Gómez del Moral, Manuel
  • Cubero, Francisco Javier
  • Blumberg, Richard S.
  • Martínez-Naves, Eduardo
[Introduction]: The Unfolded Protein Response, a mechanism triggered by the cell in response to Endoplasmic reticulum stress, is linked to inflammatory responses. Our aim was to identify novel Unfolded Protein Response-mechanisms that might be involved in triggering or perpetuating the inflammatory response carried out by the Intestinal Epithelial Cells in the context of Inflammatory Bowel Disease. [Methods]: We analyzed the transcriptional profile of human Intestinal Epithelial Cell lines treated with an Endoplasmic Reticulum stress inducer (thapsigargin) and/or proinflammatory stimuli. Several genes were further analyzed in colonic biopsies from Ulcerative Colitis patients and healthy controls. Lastly, we generated Caco-2 cells lacking HMGCS2 by CRISPR Cas-9 and analyzed the functional implications of its absence in Intestinal Epithelial Cells. [Results]: Exposure to a TLR ligand after thapsigargin treatment resulted in a powerful synergistic modulation of gene expression, which led us to identify new genes and pathways that could be involved in inflammatory responses linked to the Unfolded Protein Response. Key differentially expressed genes in the array also exhibited transcriptional alterations in colonic biopsies from active Ulcerative Colitis patients, including NKG2D ligands and the enzyme HMGCS2. Moreover, functional studies showed altered metabolic responses and epithelial barrier integrity in HMGCS2 deficient cell lines. [Conclusion]: We have identified new genes and pathways that are regulated by the Unfolded Protein Response in the context of Inflammatory Bowel Disease including HMGCS2, a gene involved in the metabolism of Short Chain Fatty Acids that may have an important role in intestinal inflammation linked to Endoplasmic Reticulum stress and the resolution of the epithelial damage., This work was supported by grants from Ministerio de Ciencia e Innovación (MCIN) from Spain [SAF2016-78711R and PID202-11794 to EM-N and FJC]; Comunidad de Madrid [B2017/BMD-3727 to EM-N and FJC]; Comunidad de Madrid (REACT-UE, ANTICIPA-CM Ref. PR38/21-24) to E.M-N and HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 to FJC the European Union’s Horizon 2020 research and innovation program [ERC-2016-Consolidator Grant 725091 to DS]; MCIN/AEI/10.13039/501100011033 [PID2019-108157RB to DS]; la Caixa Foundation (ID 100010434) [LCF/BQ/PR20/11770008 to SW]; Instituto de Salud Carlos III (ISCIII) [PI18/00348 to VE]; ISCIII [PI21/01641 to RT-R]; Spanish National Research and Development Plan, ISCIII and FEDER [PI17/02303 and PI20/01837 to SR-P]; Proyecto Desarrollo Tecnológico [DTS19/00111 to SR-P], AEI/MICIU EXPLORA Project [BIO2017-91272-EXP to SR-P]; Programa Estratégico Instituto de Biología y Genética Molecular (IBGM), Junta de Castilla y León (CCVC8485) [PID2019-104218RB-I00 to DB]; NIH [DK088199 to RB] and Universidad Complutense de Madrid (UCM 920631) [CT42/18-CT43/18 and EB15/21 to BM-A]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Supplementary material to: Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

  • Zheng, Kang
  • Hao, Fengjie
  • Medrano-García, Sandra
  • Chen, Chaobo
  • Guo, Feifei
  • Morán-Blanco, Laura
  • Rodríguez-Perales, Sandra
  • Torres-Ruiz, Raúl
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Gómez del Moral, Manuel
  • Regueiro, José R.
  • Martínez-Naves, Eduardo
  • Ramadan Mohamed, Mohamed
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gilbert-Ramos, Albert
  • Guixé-Muntet, Sergi
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andreea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Frutos, María Dolores
  • Ramos-Molina, Bruno
  • Herranz, José María
  • Ávila, Matías A.
  • Nevzorova, Yulia A.
  • Fernández-Malavé, Edgar
  • Cubero, Francisco Javier
Supplementary methods, tables (1-4) and figures legends (1-10)., Progressive hepatic damage and fibrosis are major features of chronic liver diseases of different etiology, yet the underlying molecular mechanisms remain to be fully defined. N-RAS, a member of the RAS family of small guanine nucleotide-binding proteins also encompassing the highly homologous H-RAS and K-RAS isoforms, was previously reported to modulate cell death and renal fibrosis; however, its role in liver damage and fibrogenesis remains unknown. Here, we approached this question by using N-RAS deficient (N-RAS−/−) mice and two experimental models of liver injury and fibrosis, namely carbon tetrachloride (CCl4) intoxication and bile duct ligation (BDL). In wild-type (N-RAS+/+) mice both hepatotoxic procedures augmented N-RAS expression in the liver. Compared to N-RAS+/+ counterparts, N-RAS−/− mice subjected to either CCl4 or BDL showed exacerbated liver injury and fibrosis, which was associated with enhanced hepatic stellate cell (HSC) activation and leukocyte infiltration in the damaged liver. At the molecular level, after CCl4 or BDL, N-RAS−/− livers exhibited augmented expression of necroptotic death markers along with JNK1/2 hyperactivation. In line with this, N-RAS ablation in a human hepatocytic cell line resulted in enhanced activation of JNK and necroptosis mediators in response to cell death stimuli. Of note, loss of hepatic N-RAS expression was characteristic of chronic liver disease patients with fibrosis. Collectively, our study unveils a novel role for N-RAS as a negative controller of the progression of liver injury and fibrogenesis, by critically downregulating signaling pathways leading to hepatocyte necroptosis. Furthermore, it suggests that N-RAS may be of potential clinical value as prognostic biomarker of progressive fibrotic liver damage, or as a novel therapeutic target for the treatment of chronic liver disease., This work was supported by the MICINN Retos RTI2018-095673-B-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, all of which were co-funded with FEDER funds, AMMF 2018/117, COST Action CA17112 and Comunidad de Madrid S2022/BMD-7409. This project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No. 101095679. The research group belongs to the validated Research Groups Ref. 970935 Liver Pathophysiology, 920631 Lymphocyte Immunobiology and IBL-6 (imas12-associated). KZ was supported by the China Scholarship Council. SM-G was supported by a predoctoral scholarship from Complutense University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

  • Marañón, Patricia
  • Rey, Esther
  • Isaza, Stephania C.
  • Wu, Hanghang
  • Rada, Patricia
  • Choya-Foces, Carmen
  • Martínez-Ruiz, Antonio
  • Martín, M. Ángeles
  • Ramos, Sonia
  • García-Monzón, Carmelo
  • Cubero, Francisco Javier
  • Valverde, Ángela M.
  • González-Rodríguez, Águeda
Acetaminophen (APAP)-induced liver injury is one of the most prevalent causes of acute liver failure (ALF). We assessed the role of the bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 in APAP-induced hepatotoxicity. The molecular mechanisms that regulate the balance between cell death and survival and the response to oxidative stress induced by APAP was assessed in cultured human hepatocyte-derived (Huh7) cells treated with pharmacological inhibitors of ALK receptors and with modulated expression of ALK2 or ALK3 by lentiviral infection, and in a mouse model of APAP-induced hepatotoxicity. Inhibition of ALK3 signalling with the pharmacological inhibitor DMH2, or by silencing of ALK3, showed a decreased cell death both by necrosis and apoptosis after APAP treatment. Also, upon APAP challenge, ROS generation was ameliorated and, thus, ROS-mediated JNK and P38 MAPK phosphorylation was reduced in ALK3-inhibited cells compared to control cells. These results were also observed in an experimental model of APAP-induced ALF in which post-treatment with DMH2 after APAP administration significantly reduced liver tissue damage, apoptosis and oxidative stress. This study shows the protective effect of ALK3 receptor inhibition against APAP-induced hepatotoxicity. Furthermore, findings obtained from the animal model suggest that BMP signalling might be a new pharmacological target for the treatment of ALF., This study was supported by grants RTI2018-094203-B-I00 (to AMR), PID2020-11794RB-IOO (to FJC), PID2021-124688OB-I00 (to AMR) and PID2021-122766OB-100 (to AMV) and funded by MCIN/AEI/10.13039/501100011033 (Spain) and “ERDF A way of making Europe” by the European Union; the European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, funded by the European Union, and COST Action CA17112, supported by COST (European Cooperation in Science and Technology), to FJC, and contract CP19/00032, and grants PI16/00853 and PI19/00123 from Instituto de Salud Carlos III (ISCIII, Spain), partially funded by FEDER, and CIBERDEM (ISCIII, Spain) to AGR. FJC belongs to the validated Research Groups Ref. 970935 "Liver Pathophysiologÿ, 920631 "Lymphocyte immunobiologÿ, 920361 “Inmunogenética e inmunología de las mucosas” and IBL-6 (imas12-associated). CCF is supported by grant FPU18/03475 from the Ministerio de Universidades (Spain), partially funded by FEDER. PMB is supported by a research contracts (PEJD-2018-PRE/BMD-9500PEJ-2020-AI/BMD-19491) funded by Comunidad de Madrid (Spain). SCI is supported by a predoctoral contract (FI20-00296) from ISCIII/FEDER (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cirrhosis-downregulated LSECtin can be retrieved by cytokines, shifts the TLR-induced LSECs secretome and correlates with the hepatic Th response

  • Martínez-López, Sebastián
  • Ángel-Gomis, Enrique
  • Gómez-Hurtado, Isabel
  • Fernández-Iglesias, Anabel
  • Morante, Javier
  • Gracia-Sancho, Jordi
  • Boix, Paula
  • Cubero, Francisco Javier
  • Zapater, Pedro
  • Caparrós, Esther
  • Francés, Rubén
[Background and aims]: We evaluated tolerogenic C-type lectin LSECtin loss in cirrhosis and its potential regulation by cytokines., [Methods]: Liver tissue from patients with cirrhosis and healthy controls, immortalised and generated LSECtin-CRISPR immortalised LSECs, and murine primary LSECs from the CCl4 model were handled., [Results]: LSECtin expression was reduced in liver tissue from cirrhotic patients, and it decreased from compensated to decompensated disease. Increased phosphorylation of MAPK, Akt and NFkB was observed upon LSECtin stimulation in LSEC murine cell line, showing a pattern of inflammatory and chemotactic cytokines either restrained (IL-10, CCL4) or unrestrained (TNF-α, IL-1β, IL-6, CCL2). CD44 attenuated whereas LAG-3 increased all substrates phosphorylation in combination with TLR4 and TLR2 ligands except for NFkB. TNF-α, IL-1 β, IL-6 and CCL2 were restrained by LSECtin crosslinking on TLRs studied. Conversely, IL-10 and CCL4 were upregulated, suggesting a LSECtin-TLRs synergistic effect. Also, LSECtin was significantly induced after IL-13 stimulation or combined with anti-inflammatory cytokines in cirrhotic and immortalised LSECs. Th17 and regulatory T cells were progressively increased in the hepatic tissue from compensated to decompensated patients. A significant inverse correlation was present between gene expression levels of CLEC4G/LSECtin and RORγT and FOXP3 in liver tissues., [Conclusion]: LSECtin restrains TLR proinflammatory secretome induced on LSECs by interfering immune response control, survival and MAPKs signalling pathways. The cytokine-dependent induction of LSECtin and the association between LSECtin loss and Th17 cell subset expansion in the liver, provides a solid background for exploring LSECtin retrieval as a mechanism to reprogram LSEC homeostatic function hampered during cirrhosis., This work was supported by grants from the Ministerio de Ciencia e Innovación PID2019-107036RB-I00 and PID2020-117941RB-I00, Instituto de Salud Carlos III PMP21/0082, PI20/00220 and DTS22/00010, EU Horizon-HLTH-2022-STAYHLTH-02 under agreement No. 101095679, Generalitat Valenciana Prometeo 2021/033, Comunidad de Madrid ExoHep2 S2022/BMD-7409 and AGAUR-Generalitat Catalunya (2021 SGR 01322 and 2021 PROD 00036). CIBEREHD is funded by the Instituto de Salud Carlos III using grants cofinanced by the European Development Regional Fund “A way to achieve Europe” (EDRF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

  • Lamas-Paz, Arantza
  • Hionides-Gutiérrez, Alejandro
  • Guo, Feifei
  • Jorquera, Gonzalo
  • Morán-Blanco, Laura
  • Benedé-Ubieto, Raquel
  • Mesquita, Mariana
  • Estévez-Vázquez, Olga
  • Zheng, Kang
  • Mazariegos, Marina
  • Vázquez-Ogando, Elena
  • Blázquez-López, Elena
  • Asensio, Iris
  • Mutlu, Beste
  • Gomez-Santos, Beatriz
  • Peligros, María Isabel
  • Vaquero, Javier
  • Bañares, Rafael
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
  • Martínez-Naves, Eduardo
  • Sanz-García, Carlos
  • Mohamed, Mohamed Ramadan
  • Tesolato, Sofía
  • Iniesta, Pilar
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Martínez-Alcocer, Ana
  • Sanfeliu-Redondo, David
  • Fernández-Iglesias, Anabel
  • Gracia-Sancho, Jordi
  • Coll, Mar
  • Graupera, Isabel
  • Ginès, Pere
  • Ciudin, Andrea
  • Rivera-Esteban, Jesús
  • Pericàs, Juan M.
  • Ávila, Matías A.
  • Frutos, Maria Dolores
  • Martínez-Cáceres, Carlos Manuel
  • Ramos-Molina, Bruno
  • Aspichueta, Patricia
  • Puigserver, Pere
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
[Background & Aims] Expression of P21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present study, we investigated the function of CDKN1A in SLD., [Methods] CDKN1A expression levels were evaluated in different patient cohorts with SLD, fibrosis, and advanced chronic liver disease (ACLD). Cdkn1a-/- and Cdkn1a+/+ mice were fed with either a Western diet (WD), a Lieber-DeCarli (LdC) diet plus multiple EtOH (ethanol) binges, or a DuAL diet (metabolic dysfunction-associated fatty liver disease and alcohol-related liver). Primary hepatocytes were isolated and functional assays performed., [Results] A significant increase in CDKN1A expression was observed in patients with steatohepatitis and fibrosis (with a positive correlation with both NAFLD Activity Score and fibrosis staging scores), cirrhosis and ACLD. Cdkn1a+/+ mice, fed a DuAL diet exhibited liver injury and cell death increased reactive oxygen species (ROS), and markers of senescence (γH2AX, β-GAL, Cdkn1a/p53) contributing to steatosis and inflammation. In contrast, Cdkn1a-/- mutant mice showed a significant decrease in senescence-associated markers as well as in markers of liver injury, hepatic steatosis and an increase in fatty acid oxidation and reduction in free fatty acid uptake as well as de novo lipogenesis. Mechanistically, activation of the AMPK-SIRT3 was observed in Cdkn1a-deleted animals., [Conclusions] Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis via the AMPK-SIRT3 axis. CDKN1A expression was found to be directly correlated with increased severity of NAFLD Activity Score and fibrosis in patients with SLD. CDKN1A could be a potential theragnostic target for the treatment of metabolic dysregulation in patients with SLD, with and without alcohol consumption., [Impact and implications] Expression of p21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD), but the molecular mechanisms remain elusive. Interestingly, in this study we found that Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis, via the AMPK-SIRT3 axis. Translationally, Cdkn1a expression was found to be directly correlated with increased severity of NAFLD Activity Score (NAS) and fibrosis in SLD patients, and therefore, CDKN1A might be used potential theragnostic target for the treatment of metabolically induced SLD, with and without alcohol consumption., This work was supported by the MICIU/AEI/10.13039/501100011033 PID2020-113299RA-I00, PID2020-11782RB-I00, PID2020-117941RB-I00, PID2021-124425OB-I00, PID2023-150260OB-I00, and PID2023-151347OB-I00, all of which were co-financed with Fondos FEDER, UE, Basque Government, Department of Education (IT1476-2), the Institute of Health Carlos III (ISCIII) (awards numbers PI20/00505 and PI23/00171), EXOHEP2-CM (S2022/BMD-7409), HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679 and the Dynamic Resilience Program - Wellcome Leap. CSG is an Atracción de Talento (CAM) 2019 2019-T1/BMD-13313. The research group belongs to the validated Research Groups Ref. 970935 ‘Liver Pathophysiology’, 920631 ‘Lymphocyte immunobiology’, 920361 ‘Inmunogenética e inmunología de las mucosas’ and IBL-6 (imas12-associated). ALP and AH are recipients of a UCM Real Colegio Complutense (RCC) Harvard - Santander scholarships CT17/17 and CT15/23, respectively. BRM is supported by the ‘Miguel Servet Type I’ program (CP19/00098, funded by the Institute of Health Carlos III, Spain; co-funded by the ‘Fondo Europeo de Desarrollo Regional’)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea Usandizaga, Naroa
  • Bravo, Miren
  • Egia Mendikute, Leire
  • Abecia, Leticia
  • Serrano Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos García, Marc
  • Rodríguez Agudo, Rubén
  • Araujo Legido, Raquel
  • López Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo Ortega, Sofía
  • González Recio, Irene
  • Gil Pitarch, Clàudia
  • Peña Cearra, Ainize
  • Simón, Jorge
  • Benede Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar Bermeo, Julio
  • Martí, Nuria
  • Varela Rey, Marta
  • Falcón Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero Palero, Francisco Javier
  • Saura, Domingo
  • Martínez Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Sancho Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J.G.
  • Martín, Franz
  • Martínez Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.